Gilead is committed to advancing care for people around the world by bringing forward medicines to address unmet medical needs in virology, oncology, invasive fungal disease and inflammation. We do this through internal research and development, as well as through collaborations with academic and industry partners.
Since 1987, Gilead has delivered more than 25 innovative medicines, helping to improve treatment for people living with diseases such as HIV, viral hepatitis, cancer and other conditions.
March 2025 UKI-UNB-0576
Adverse events should be reported
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.